In compliance with Regulation 92(1) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, we enclose herewith extracts of the newspaper advertisement ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aspira Pathlab & Diagnostics Limited posted strong Q2 FY26 results, with total operating income rising to ₹809.28 lakhs from ₹524.80 lakhs in Q2 FY25, a year-on-year jump of about 54%. Net profit after tax surged to ₹183.54 lakhs from ₹46.94 lakhs in the same quarter last year, nearly 4x growth. For the half year (H1 FY26), revenue climbed to ₹1,334.08 lakhs vs ₹1,081.49 lakhs, while profit rose to ₹230.49 lakhs vs ₹97.36 lakhs. Half-yearly EPS stood at ₹2.24 vs ₹0.95 last year. The company also acquired the business of Aspira DNA Diagnostics Gujarat LLP on a slump sale basis for ₹13 lakhs, effective July 1, 2025, which contributed to the current quarter's performance. Results were reviewed by the auditors with an unmodified opinion and approved by the Board on November 12, 2025. Note: The filing was tagged to Covidh Technologies Ltd on BSE but the actual document pertains to Aspira Pathlab & Diagnostics Ltd.
Sharp improvement in both revenue and profitability signals strong business momentum and benefits from the recent LLP acquisition. The near-tripling of quarterly profit is positive for shareholders and may support the stock price in the short term.